All In Biotech

Drug Trial Radar · NCT04468100

Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis

A Multicenter Prospective Randomized Comparative Study of Pharmacokinetics, Clinical Efficacy and Safety of Tigerase® (JSC GENERIUM, Russia) vs. Pulmozyme® (Hoffmann-La Roche, Switzerland) as Part of Complex Therapy in Patients With Cystic Fibrosis

Last checked: Nov 20, 2026Latest source record: Jul 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Aug 30, 2017

Primary completion

May 16, 2018

Study completion May 16, 2018

Sponsor

Lead sponsor
AO GENERIUMIndustry
Sponsor type
Industry
First posted
Jul 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is a multicenter, open-label, randomized, parallel-group study of the efficacy and safety of Tigerase® compared Pulmozyme® in patients with Cystic Fibrosis

Conditions

  • Cystic Fibrosis
  • Fibrosis

Interventions

  • Tigerase®Biological

    2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days

  • Pulmozyme®Biological

    2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in forced expiratory volume in the first second of a forced expiratory maneuver (FEV1) compared to baselineTime frame: FEV1 - forced expiratory volume in the first second of a forced expiratory maneuver by standard spirometry

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Chelyabinsk Regional Clinical hospital

    Chelyabinsk, Russia

  • City Clinical Hospital named after D.D. Pletnev

    Moscow, Russia

  • City Multidisciplinary Hospital No. 2

    Saint Petersburg, Russia

  • Regional clinical Hospital

    Saratov, Russia

  • Scientific medical center of General Medicine and pharmacologies

    Stavropol, Russia

  • Tomsk national medical research Center of the Russian Academy of Sciences, Genetic Clinic Research Institute medical genetics

    Tomsk, Russia

  • Volgograd State Medical University, Department of clinical pharmacology and intensive care

    Volgograd, Russia

  • Children's Clinical Hospital No. 1 ", Cystic Fibrosis center

    Yaroslavl, Russia

  • Clinical hospital No. 2

    Yaroslavl, Russia

  • Regional Clinical Hospital

    Barnaul, Altayskiy Kray, Russia

  • Republican Clinical hospital named after G.G. Kuvatov

    Ufa, Bashkortostan Republic, Russia

  • Crimean federal university named after V.I.Vernadsky

    Simferopol, Crimea Republic, Russia

  • Sverdlovsk Regional clinical hospital No. 1

    Yekaterinburg, Sverdlovsk Oblast, Russia

  • Kazan state medical University of Ministry of health, Hospital Therapy Department

    Kazan', Tatarstan Republic, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.